DeepView® System Achieves 95.3% Accuracy Evaluation as Published in Burns Journal

Rhea-AI Summary

Spectral AI's (NASDAQ: MDAI) DeepView® System has achieved a remarkable 95.3% accuracy in burn healing assessment, as published in the prestigious Burns journal. The multi-center clinical study validates the system's effectiveness in using AI-driven multi-spectral imaging to predict burn healing potential across diverse clinical settings.

The technology enables clinicians to make earlier, more informed decisions about healing time and surgical requirements, potentially improving patient outcomes. This publication in Burns, a leading peer-reviewed medical journal of the International Society for Burn Injuries, represents the first multi-center evaluation of AI-enhanced multispectral imaging in burn assessment.

Positive

• Achieved high accuracy rate of 95.3% in burn healing assessment
• Successfully published results in prestigious Burns medical journal
• First multi-center evaluation demonstrating effectiveness across different clinical settings
• Technology enables earlier clinical decision-making for treatment

Negative

• None.

Insights

Medical Device Research Analyst

Spectral AI's DeepView achieved 95.3% accuracy in burn assessment in a multi-center study, validating its clinical potential for improved treatment decisions.

The clinical validation of Spectral AI's DeepView System in the prestigious Burns journal represents a significant milestone for the company's AI-driven burn assessment technology. The reported 95.3% accuracy rate in this multi-center study is particularly noteworthy as it demonstrates robust performance across different clinical settings - a critical factor for widespread adoption in medical devices.

The core value proposition of DeepView lies in its ability to provide objective, data-driven assessments of burn depth using multi-spectral imaging combined with AI algorithms. This addresses a fundamental challenge in burn care where traditional visual assessments are highly subjective and variable between clinicians. Accurate burn depth assessment is crucial as it directly determines treatment pathways - whether a burn will heal naturally or require surgical intervention.

From a regulatory and commercialization perspective, this peer-reviewed validation strengthens DeepView's position substantially. Multi-center studies carry significant weight with regulatory bodies like FDA, as they demonstrate reproducibility across different settings and patient populations. For potential hospital customers, this published evidence in a respected journal provides the clinical validation necessary to justify adoption and reimbursement discussions.

The technology's ability to enable earlier decision-making regarding healing time and surgical necessity directly translates to improved patient outcomes through faster appropriate interventions and potentially reduced unnecessary surgeries. This represents both clinical benefit and potential cost savings to healthcare systems, strengthening the economic case for adoption alongside the clinical one.

DALLAS, May 27, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ: MDAI) (“Spectral AI” or the “Company”), a leading developer of the AI-driven DeepView^® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential today announced that the Company’s DeepView System has been featured in the journal Burns as part of a clinical study in which it achieved a 95.3% overall accuracy assessment as compared to traditional subjective assessments.

Chris Lewis, a lead author of the study, said "We are thrilled to see our experience with the DeepView technology published in Burns. This research highlights the transformative role of this cutting-edge technology in evaluating burn depth. By providing clinicians with data-driven insights, DeepView empowers earlier decision-making regarding healing time and the necessity of surgical debridement, ultimately improving patient outcomes. The study represents the first multi-center evaluation of AI-enhanced multispectral imaging in burn assessment which demonstrates the DeepView System’s effectiveness across diverse clinical settings. Being published in Burns is a testament to the clinical importance of the DeepView^® device. The technology is not only innovative but also has the potential to revolutionize burn care on a global scale.”

Burns: The Journal of the International Society for Burn Injuries is a prominent, peer-reviewed medical journal dedicated to research and advancements in the field of burn care, wound healing, and thermal injury treatment. It serves as a critical platform for clinicians, surgeons, and researchers worldwide to share groundbreaking findings, innovative techniques, and best practices in burn management.

About Spectral AI

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown^®” with its DeepView^® System. The DeepView^® System is being developed as a predictive device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView^® System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about the DeepView^® System, visit www.spectral-ai.com.

Forward-Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements. 

Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. 

For Media and Investor Relations, please contact:

David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email: dk@atlcp.com

FAQ

What accuracy rate did Spectral AI's (MDAI) DeepView System achieve in burn assessment?

The DeepView System achieved a 95.3% overall accuracy assessment compared to traditional subjective assessments, as published in the Burns journal.

How does Spectral AI's DeepView System work for burn assessment?

The DeepView System uses multi-spectral imaging and AI algorithms to predict burn healing potential, enabling clinicians to make earlier decisions about healing time and surgical requirements.

What is significant about the Burns journal publication for Spectral AI (MDAI)?

The publication represents the first multi-center evaluation of AI-enhanced multispectral imaging in burn assessment, validating the technology's effectiveness across diverse clinical settings.

What are the clinical benefits of Spectral AI's DeepView System?

The system provides clinicians with data-driven insights for earlier decision-making regarding healing time and surgical debridement necessity, potentially improving patient outcomes.